Evidence mapPaperPMID 29503172Full record

ArticleThe lancet. Diabetes & endocrinology2018

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.

Emma Ahlqvist, Petter Storm, Annemari Käräjämäki, Mats Martinell, Mozhgan Dorkhan, Annelie Carlsson, Petter Vikman, Rashmi B Prasad, Dina Mansour Aly, Peter Almgren and 14 more

6 registry-linked trialsOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 1,090 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,090citing papers in PubMed, 2 pooled it
144.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06120556 completedstarted 2023, after this paper: background citation

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes: an Italian Monocentric Retrospective Study

Ran2023Enrolled130Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsGLP-1 receptor agonist
PMID 31047901PMID 32699108other papers from this trial
Open the trial in the graph
NCT05166447 enrolling by invitationnot on this mapstarted 2021, after this paper: background citation

Twenty-year Follow-up of the Inter99 Cohort

TypeobservationalSponsorBispebjerg HospitalRan2021 to 2028Enrolled4,000ConditionsCoronary Heart Disease, Acute Myocardial Infarction, Cardiovascular Diseases, Type 2 Diabetes
NCT06706609 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population

TypeobservationalSponsorGetz PharmaRan2025 to 2025Enrolled394ConditionsDiabetes Mellitus, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus Type 1 and 2
NCT06876818 active not recruitingnot on this mapstarted 2024, after this paper: background citation

Predictive Cardio-Metabolic Trascrictomics Trajectories In The Barilla Offspring Follow-Up STUDY: The PREDICT-OMICS Study.

TypeobservationalSponsorAzienda Ospedaliero-Universitaria di ParmaRan2024 to 2025Enrolled110ConditionsHealthy VolunteerArmsEvaluation of transcriptomic and cardio-metabolic profiles
NCT07064499 active not recruitingnot on this mapstarted 2023, after this paper: background citation

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes: a Real-life Multicentre Observational Study in Belgium.

TypeobservationalSponsorErasme University HospitalRan2023 to 2027Enrolled440ConditionsType 2 Diabetes
NCT07461805 recruitingnot on this mapstarted 2025, after this paper: background citation

Caracterización de Subgrupos de Personas Con Diabetes Tipo 1: análisis de características clínicas y glucométricas Utilizando Una aproximación de Inteligencia Artificial

Typeobservational_patient_registrySponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauRan2025 to 2028Enrolled800ConditionsType 1 Diabetes Mellitus
3 · Its place in the literature

Who cites it

1,090 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,205 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Prediabetes Subgroups, Type 2 Diabetes Risk, and Differential Effects of Preventive Interventions.The Journal of clinical endocrinology and metabolism · 2025 · on this map
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

1,030 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Emma AhlqvistLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Petter StormLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Annemari KäräjämäkiDepartment of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland; Diabetes Center, Vaasa Health Care Center, Vaasa, Finland.
Mats MartinellDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Mozhgan DorkhanLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Annelie CarlssonLund University Diabetes Centre, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Petter VikmanLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Rashmi B PrasadLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Dina Mansour AlyLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Peter AlmgrenLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Ylva WessmanLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Nael ShaatLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Peter SpégelLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden; Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden.
Hindrik MulderLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Eero LindholmLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Olle MelanderLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Ola HanssonLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Ulf MalmqvistClinical Research and Trial Center, Lund University Hospital, Sweden.
Åke LernmarkLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.
Kaj LahtiDepartment of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland; Diabetes Center, Vaasa Health Care Center, Vaasa, Finland.
Tom ForsénFolkhälsan Research Center, Helsinki, Finland.
Tiinamaija TuomiFolkhälsan Research Center, Helsinki, Finland; Abdominal Center, Endocrinology, Helsinki University Central Hospital, Research Program for Diabetes and Obesity, University of Helsinki, Helsinki, Finland; Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland.
Anders H RosengrenLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden; Department of Neuroscience and Physiology, Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Leif GroopLund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden; Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. Electronic address: leif.groop@med.lu.se.
Lund University · SEUniversity of Helsinki · FIVaasa Central Hospital · FIFolkhälsans Forskningscentrum · FIUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes is presently classified into two main forms, type 1 and type 2 diabetes, but type 2 diabetes in particular is highly heterogeneous. A refined classification could provide a powerful tool to individualise treatment regimens and identify individuals with increased risk of complications at diagnosis.

methodsWe did data-driven cluster analysis (k-means and hierarchical clustering) in patients with newly diagnosed diabetes (n=8980) from the Swedish All New Diabetics in Scania cohort. Clusters were based on six variables (glutamate decarboxylase antibodies, age at diagnosis, BMI, HbA

findingsWe identified five replicable clusters of patients with diabetes, which had significantly different patient characteristics and risk of diabetic complications. In particular, individuals in cluster 3 (most resistant to insulin) had significantly higher risk of diabetic kidney disease than individuals in clusters 4 and 5, but had been prescribed similar diabetes treatment. Cluster 2 (insulin deficient) had the highest risk of retinopathy. In support of the clustering, genetic associations in the clusters differed from those seen in traditional type 2 diabetes.

interpretationWe stratified patients into five subgroups with differing disease progression and risk of diabetic complications. This new substratification might eventually help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.

fundingSwedish Research Council, European Research Council, Vinnova, Academy of Finland, Novo Nordisk Foundation, Scania University Hospital, Sigrid Juselius Foundation, Innovative Medicines Initiative 2 Joint Undertaking, Vasa Hospital district, Jakobstadsnejden Heart Foundation, Folkhälsan Research Foundation, Ollqvist Foundation, and Swedish Foundation for Strategic Research.

Indexed as

AdultCluster AnalysisCohort StudiesDiabetes ComplicationsDiabetes MellitusDisease ProgressionFemaleHumansMaleProspective StudiesRisk Factors

Identifiers

PMID29503172
OpenAlexW2790501791

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.